-
Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine
Kooij, K. W., Wit, F. W. N. M., van Zoest, R. A., Schouten, J., Kootstra, N. A., van Vugt, M., Prins, M., Reiss, P. & van der Valk, M., 2016, In: AIDS (London, England). 30, 11, p. 1771-1780Research output: Contribution to journal › Article › Academic › peer-review
-
Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection
van der Valk, M., Zaaijer, H. L., Kater, A. P. & Schinkel, J., 2017, In: Journal of Hepatology. 66, 1, p. 242-243Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life
Willemse, S. B., Baak, L. C., Kuiken, S. D., van der Sluys Veer, A., Lettinga, K. D., van der Meer, J. T. M., Depla, A. C. T. M., Tuynman, H., van Nieuwkerk, C. M. J., Schinkel, C. J., Kwa, D., Reesink, H. W. & van der Valk, M., Dec 2016, In: Journal of viral hepatitis. 23, 12, p. 950-954 5 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
-
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
Marshall, A. D., Willing, A. R., Kairouz, A., Cunningham, E. B., Wheeler, A., O'Brien, N., Perera, V., Ward, J. W., Hiebert, L., Degenhardt, L., Hajarizadeh, B., Colledge, S., Hickman, M., Jawad, D., Lazarus, J. V., Matthews, G. V., Scheibe, A., Vickerman, P., Dore, G. J., Grebely, J., & 2 others , 1 Apr 2024, In: The Lancet Gastroenterology and Hepatology. 9, 4, p. 366-382 17 p.Research output: Contribution to journal › Review article › Academic › peer-review
-
Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study
Vasylyev, M., Wit, F. W. N. M., Jordans, C. C. E., Soetekouw, R., van Lelyveld, S. F. L., Kootstra, G-J., Delsing, C. E., Ammerlaan, H. S. M., van Kasteren, M. E. E., Brouwer, A. E., Leyten, E. M. S., Claassen, M. A. A., Hassing, R-J., den Hollander, J. G., van den Berge, M., Roukens, A. H. E., Bierman, W. F. W., Groeneveld, P. H. P., Lowe, S. H., van Welzen, B. J., & 3 others , 1 Apr 2024, In: Open forum infectious diseases. 11, 4, ofae160.Research output: Contribution to journal › Article › Academic › peer-review
-
All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019
Requena, M-B., Protopopescu, C., Stewart, A. C., van Santen, D. K., Klein, M. B., Jarrin, I., Berenguer, J., Wittkop, L., Salmon, D., Rauch, A., Prins, M., van der Valk, M., Sacks-Davis, R., Hellard, M. E., Carrieri, P. & InCHEHC Collaboration, 1 Feb 2024, In: International Journal of Drug Policy. 124, 104311.Research output: Contribution to journal › Article › Academic › peer-review
- All publications